期刊文献+

纳米技术应用于帕金森病治疗的研究进展

Research Progress in the Application of Nanotechnology for the Treatment of Parkinson’s Disease
原文传递
导出
摘要 帕金森病(PD)的治疗策略主要有药物治疗、基因治疗、干细胞治疗和物理刺激疗法,这些治疗方法均存在一定的缺陷,纳米技术在解决这些问题中展现了独特的优势。纳米材料不仅是递送药物和基因的良好载体,而且一些纳米材料还表现出神经保护作用;利用纳米技术可以辅助PD的干细胞治疗,并有望刺激和调控神经活性。为了更好地认识纳米技术治疗PD的研究现状,应用该技术解决PD治疗中所面临的挑战,对纳米技术在治疗PD中的应用进展作一综述。 The treatment strategies for Parkinson’s disease(PD) principally include drug therapy, gene therapy, stem cell therapy and physical neurostimulation, yet all these therapies have certain defects. Nanotechnology, however, stands out with its unique advantages. Nanomaterials function as excellent carriers to deliver drugs and genes, some of which also have neuroprotective effects. Besides, it is promising to utilize nanotechnology in stem cell therapy or neurostimulation. This paper reviews the research and trend of nanotechnology in PD therapy, aiming at a better comprehension of its application so as to deal with the challenges for the treatment of PD.
作者 蔡雯雯 李建平 张孟伟 王家奇 郝津津 顾宁 CAI Wenwen;LI Jianping;ZHANG Mengwei;WANG Jiaqi;HAO Jinjin;GU Ning(School of Medicine,Southeast University,Nanjing 210009,China;School of Biological Science and Medical Engineering,Southeast University,Nanjing 210096,China)
出处 《药学进展》 CAS 2020年第2期133-144,共12页 Progress in Pharmaceutical Sciences
基金 国家自然科学基金国际合作重点项目(No.61420106012) 国家重大研发计划(No.2017YFA0104301)。
关键词 帕金森病 纳米技术 纳米材料 药物治疗 基因治疗 干细胞治疗 Parkinson’s disease nanotechnology nanomaterial drug therapy gene therapy stem cell therapy
  • 相关文献

参考文献3

二级参考文献35

  • 1Drouot X, Oshino S, Jarraya B, et al. Functional recovery in a primate model of Parkinson's disease following motor cortex stimulation. Neuron, 2004, 44:769-778.
  • 2Benvenuti E, Cecchi F, Colombini A, et al. Extradural motor cortex stimulation as a method to treat advanced Parkinson's disease: new perspectives in geriatric medicine. Aging Clin Exp Res, 2006, 18:347-348.
  • 3Bjorklund LM, Sanchez-Pernaute R, Chung S, et al. Embryonic stem cells develop into functional dopaminergic neurons after transplantation in a Parkinson rat model. Proc Natl Acad Sci USA, 2002, 99:2344-2349.
  • 4Piccini P, Pavese N, Hagell P, et al. Factors affecting the clinical outcome after neural transplantation in Parkinson's disease. Brain, 2005, 128(Pt 12):2977-2986.
  • 5Wernig M, Zhao JP, Pruszak J, et al. Neurons derived from reprogrammed fibroblasts functionally integrate into the fetal brain and improve symptoms of rats with Parkinson's disease. Proc Natl Acad Sci USA, 2008, 105:5856-5861.
  • 6Kaplitt MG, Feigin A, Tang C, et al. Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase Ⅰ trial. Lancet, 2007, 369:2097-2105.
  • 7Volz TJ, Farnsworth SJ, Rowley SD, et al. Age- dependent differences in dopamine transporter and vesicular monoautine transporter 2 function and their implications for methamphetamine neurotoxicity. Synapse, 2009, 63:147-151.
  • 8Youdim MB, Bakhle YS. Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness. Br J Pharmacol, 2006, 147 Suppl 1:287-296.
  • 9Morelli M, Carta AR, Jenner P. Adenosine A2A receptors and Parkinson's disease. Handb Exp Pharmacol, 2009, (193):589- 615.
  • 10Li J, Zhu M, Rajamani S, et al. Rifampicin inhibits alpha- synuclein fibrillation and disaggregates fibrils. Chem Biol, 2004, 11:1513-1521.

共引文献102

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部